Stereotactic body radiotherapy for stage I non-small-cell lung cancer using higher doses for larger tumors: results of the second study
Open Access
- 11 September 2017
- journal article
- clinical trial
- Published by Springer Nature in Radiation Oncology
- Vol. 12 (1) , 1-7
Abstract
Efficacy of stereotactic body radiotherapy (SBRT) in stage I non–small-cell lung cancer (NSCLC) has almost been established. In Japan, the protocol of 48 Gy in 4 fractions over 4 days has been most often employed, but higher doses may be necessary to control large tumors. Previously, we conducted a clinical study using SBRT for stage I NSCLC employing different doses depending on tumor diameter, which was closed in 2008. Thereafter, a new study employing higher doses has been conducted, which is reported here. The purpose of this study was to review the safety and effectiveness of the higher doses. We escalated the total dose for the improvement of local control for large tumors. In this study, 71 patients underwent SBRT between December 2008 and April 2014. Isocenter doses of 48, 50, and 52 Gy were administered for tumors with a longest diameter of < 1.5 cm, 1.5–3 cm, and > 3 cm, respectively. It was recommended to cover 95% of the PTV with at least 90% of the isocenter dose, and in all but one cases, 95% of the PTV received at least 80% of the prescribed dose. Treatments were delivered in 4 fractions, giving 2 fractions per week. SBRT was performed with 6-MV photons using 4 non-coplanar and 3 coplanar beams. The median follow-up period was 44 months for all patients and 61 months for living patients. Overall survival (OS) was 65%, progression-free survival (PFS) was 55%, and cumulative incidence of local recurrence (LR) was 15% at 5 years. The 5-year OS was 69% for 57 stage IA patients and 53% for 14 stage IB patients (p = 0.44). The 5-year PFS was 55 and 54%, respectively (p = 0.98). The 5-year cumulative incidence of LR was 11 and 31%, respectively (p = 0.09). The cumulative incidence of Grade ≥ 2 radiation pneumonitis was 25%. Our newer SBRT study yielded reasonable local control and overall survival and acceptable toxicity, but escalating the total dose did not lead to improved outcomes. UMIN000027231 , registered on 3 May 2017. Retrospectively registered.Keywords
This publication has 30 references indexed in Scilit:
- Lung metastases treated with stereotactic body radiotherapy: the RSSearch® patient Registry’s experienceRadiation Oncology, 2017
- A critical review of recent developments in radiotherapy for non-small cell lung cancerRadiation Oncology, 2016
- Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403International Journal of Radiation Oncology - Biology - Physics (IJROBP), 2015
- Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trialsThe Lancet Oncology, 2015
- Stereotactic Body Radiotherapy for Stage I NSCLC: The Challenge of Evidence-Based MedicineJournal of Thoracic Oncology, 2014
- Stereotactic Body Radiation Therapy for Stage I Non-small-cell Lung Cancer: A Historical Overview of Clinical StudiesJapanese Journal of Clinical Oncology, 2013
- Stereotactic Body Radiation Therapy for Inoperable Early Stage Lung CancerJAMA, 2010
- Outcome in a Prospective Phase II Trial of Medically Inoperable Stage I Non–Small-Cell Lung Cancer Patients Treated With Stereotactic Body RadiotherapyJournal of Clinical Oncology, 2009
- Stereotactic Body Radiotherapy for Primary Lung Cancer at a Dose of 50 Gy Total in Five Fractions to the Periphery of the Planning Target Volume Calculated Using a Superposition AlgorithmInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2009
- Clinical outcomes of 3D conformal hypofractionated single high-dose radiotherapy for one or two lung tumors using a stereotactic body frameInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2002